Valeant Looks To Steady The Ship With Return Of Schiller As Interim CEO
This article was originally published in The Pink Sheet Daily
Former Chief Financial Officer Howard Schiller has been appointed interim CEO of Valeant, effective immediately, while J. Michael Pearson remains hospitalized with pneumonia.
You may also be interested in...
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.